A Review of Neonatal Selective Serotonin Reuptake Inhibitor Withdrawal Syndrome

Area of Science:

• Neonatalogy
• Pharmacology
• Developmental Pediatrics

Background:

• Selective Serotonin Reuptake Inhibitor (SSRI) use during pregnancy can lead to neonatal withdrawal.
• Neonatal Selective Serotonin Reuptake Inhibitor (SSRI) withdrawal syndrome (NSWS) is often poorly defined and managed.
• Existing treatment algorithms primarily address opioid withdrawal, leaving a gap for NSWS management.

Purpose of the Study:

• To define neonatal Selective Serotonin Reuptake Inhibitor (SSRI) withdrawal syndrome (NSWS) from a developmental viewpoint.
• To outline current literature-based management strategies for NSWS, focusing on pharmaceutical interventions.
• To highlight the need for clearer guidelines and further research in NSWS treatment.

Main Methods:

• Comprehensive literature search using major scientific databases (PubMed, OVID Medline, Google Scholar, Embase, Web of Science).
• Keywords included "neonatal", "SSRI", "withdrawal", "poor neonatal adaptation", and "neonatal abstinence syndrome".
• Review focused on identifying non-pharmacologic and pharmacologic interventions described in existing studies.

Main Results:

• Non-pharmacologic care includes hydration, nutrition, and a calm environment.
• Pharmacologic management for NSWS should be individualized, potentially using clonidine, phenobarbital, or chlorpromazine for specific symptoms.
• Morphine and methadone are generally not indicated for NSWS without concurrent opioid exposure.
• Limited data exists to differentiate NSWS from neonatal opioid withdrawal.

Conclusions:

• There is a significant lack of clarity and specific guidelines for managing neonatal Selective Serotonin Reuptake Inhibitor (SSRI) withdrawal syndrome (NSWS).
• Further research and comparative studies are essential to develop evidence-based guidelines for NSWS treatment.
• Differentiating NSWS from other neonatal withdrawal syndromes is crucial for appropriate and effective care.